Healthcare >> CEO Interviews >> May 29, 2000
RAYMOND P. WARRELL, JR, MD, MBA., has been President and CEO of Genta
Incorporated since December, 1999. Dr. Warrell is internationally known
for his expertise in the clinical development of anticancer
therapeutics. Previously, he was associated on a full-time basis with
the Memorial Sloan-Kettering Cancer Center in New York, where he held
tenured positions as Member, Attending Physician and Associate
Physician-in-Chief, and also with the Joan and Sanford Weill Medical
College of Cornell University, where he was Professor of Medicine. In
the past, he served as Consultant to a number of pharmaceutical and
biotechnology companies, including Genta. In 1997, he co-founded PolaRx
Biopharmaceuticals, Inc., developers of an investigational agent for the
treatment of acute promyelocytic leukemia, and served as Chairman of its
Scientific Advisory Board. In 1998, he founded Relgen LLC a privately
held pharmaceutical company and maker of Ganite_ (gallium nitrate
injection), which is approved in the US and Canada for treatment of
cancer-related hypercalcemia. Dr. Warrell holds numerous patents for
biomedical therapeutic and diagnostic agents, primarily related to
treatment of cancer or metabolic bone disease. He is a board certified
in both Internal Medicine and Medical Oncology, and has published more
than 450 articles, book chapters, and scientific abstracts, most of
which are related to development of novel therapeutics in oncology. Dr.
Warrell received a BS in Chemistry from Emory University, a MD from the
Medical College of Georgia, and an MBA from Columbia University Graduate
School of Business. Profile
Incorporated? Then describe what you see as the business and company
today.
Dr. Warrell: Genta is an oncology development company.
